Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioventus Inc. stock logo
BVS
Bioventus
$4.01
-1.5%
$4.95
$0.86
$6.08
$317.47M0.5144,485 shs106,562 shs
DarioHealth Corp. stock logo
DRIO
DarioHealth
$1.48
+0.7%
$1.61
$0.68
$4.58
$43.92M1.66133,496 shs48,693 shs
Nyxoah S.A. stock logo
NYXH
Nyxoah
$9.97
-11.7%
$13.51
$4.00
$20.00
N/A1.555,286 shs21,452 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$3.42
+2.7%
$3.82
$1.79
$5.38
$56.05M0.91144,057 shs44,391 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioventus Inc. stock logo
BVS
Bioventus
-1.93%-10.55%-20.82%-9.96%+266.67%
DarioHealth Corp. stock logo
DRIO
DarioHealth
-2.00%+27.83%-2.97%-38.24%-54.91%
Nyxoah S.A. stock logo
NYXH
Nyxoah
+5.51%+8.56%-15.56%+19.98%+37.85%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
+1.52%+2.46%-16.54%-5.67%-28.85%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioventus Inc. stock logo
BVS
Bioventus
3.1095 of 5 stars
3.50.00.00.00.64.21.9
DarioHealth Corp. stock logo
DRIO
DarioHealth
1.6317 of 5 stars
3.51.00.00.01.80.81.3
Nyxoah S.A. stock logo
NYXH
Nyxoah
1.6199 of 5 stars
4.42.00.00.00.60.80.0
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.6427 of 5 stars
3.53.00.00.02.70.81.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioventus Inc. stock logo
BVS
Bioventus
3.00
Buy$7.6791.19% Upside
DarioHealth Corp. stock logo
DRIO
DarioHealth
3.00
Buy$5.37262.64% Upside
Nyxoah S.A. stock logo
NYXH
Nyxoah
2.83
Moderate Buy$20.60106.62% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.00
Buy$7.50119.30% Upside

Current Analyst Ratings

Latest SRTS, BVS, DRIO, and NYXH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
DarioHealth Corp. stock logo
DRIO
DarioHealth
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/20/2024
Nyxoah S.A. stock logo
NYXH
Nyxoah
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $22.00
3/20/2024
Nyxoah S.A. stock logo
NYXH
Nyxoah
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $27.00
3/14/2024
Nyxoah S.A. stock logo
NYXH
Nyxoah
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$17.00 ➝ $20.00
3/13/2024
Bioventus Inc. stock logo
BVS
Bioventus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $9.00
3/6/2024
Nyxoah S.A. stock logo
NYXH
Nyxoah
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
3/6/2024
Nyxoah S.A. stock logo
NYXH
Nyxoah
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$15.00 ➝ $20.00
3/5/2024
Nyxoah S.A. stock logo
NYXH
Nyxoah
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $20.00
2/28/2024
Nyxoah S.A. stock logo
NYXH
Nyxoah
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $18.00
2/9/2024
Nyxoah S.A. stock logo
NYXH
Nyxoah
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$10.00 ➝ $14.00
2/1/2024
Nyxoah S.A. stock logo
NYXH
Nyxoah
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$10.00 ➝ $15.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioventus Inc. stock logo
BVS
Bioventus
$512.34M0.62$0.76 per share5.25$2.80 per share1.43
DarioHealth Corp. stock logo
DRIO
DarioHealth
$20.35M2.16N/AN/A$2.14 per share0.69
Nyxoah S.A. stock logo
NYXH
Nyxoah
$4.70MN/AN/AN/A$5.08 per shareN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$24.41M2.30$0.06 per share56.80$2.98 per share1.15

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23M-$2.52N/A10.03N/A-30.49%2.25%0.62%5/21/2024 (Estimated)
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$59.43M-$1.03N/AN/AN/A-165.96%-48.84%-31.56%5/9/2024 (Estimated)
Nyxoah S.A. stock logo
NYXH
Nyxoah
-$46.77M-$1.68N/AN/AN/A-993.28%-38.58%-31.24%5/21/2024 (Estimated)
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$490K$0.03114.04N/A1.99%1.04%0.93%5/9/2024 (Confirmed)

Latest SRTS, BVS, DRIO, and NYXH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-$0.04N/A+$0.04N/AN/AN/A  
3/28/2024Q4 2023
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$0.54-$0.41+$0.13-$0.41$3.57 million$3.62 million
3/12/2024Q4 2023
Bioventus Inc. stock logo
BVS
Bioventus
$0.06$0.07+$0.01$0.24$124.84 million$135.42 million
3/5/2024Q4 2023
Nyxoah S.A. stock logo
NYXH
Nyxoah
-$0.41-$0.41N/A-$0.41$2.01 million$1.96 million    
2/8/2024Q4 2023
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.12$0.26+$0.14$0.26$12.10 million$12.57 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
N/AN/AN/AN/AN/A
Nyxoah S.A. stock logo
NYXH
Nyxoah
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioventus Inc. stock logo
BVS
Bioventus
1.66
1.53
1.01
DarioHealth Corp. stock logo
DRIO
DarioHealth
0.42
3.79
3.38
Nyxoah S.A. stock logo
NYXH
Nyxoah
0.12
4.73
4.50
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
11.76
8.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
DarioHealth Corp. stock logo
DRIO
DarioHealth
33.39%
Nyxoah S.A. stock logo
NYXH
Nyxoah
N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%

Insider Ownership

CompanyInsider Ownership
Bioventus Inc. stock logo
BVS
Bioventus
29.10%
DarioHealth Corp. stock logo
DRIO
DarioHealth
10.10%
Nyxoah S.A. stock logo
NYXH
Nyxoah
17.11%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
11.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bioventus Inc. stock logo
BVS
Bioventus
97079.17 million56.13 millionNot Optionable
DarioHealth Corp. stock logo
DRIO
DarioHealth
27629.68 million26.68 millionOptionable
Nyxoah S.A. stock logo
NYXH
Nyxoah
137N/AN/ANot Optionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3516.39 million14.57 millionOptionable

SRTS, BVS, DRIO, and NYXH Headlines

SourceHeadline
Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024
finance.yahoo.com - April 25 at 9:13 AM
Sensus Healthcare (NASDAQ:SRTS) Stock Passes Below Fifty Day Moving Average of $3.89Sensus Healthcare (NASDAQ:SRTS) Stock Passes Below Fifty Day Moving Average of $3.89
americanbankingnews.com - April 20 at 4:22 AM
Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024
globenewswire.com - April 18 at 4:05 PM
Sensus Healthcare, Inc. (NASDAQ:SRTS) Sees Large Increase in Short InterestSensus Healthcare, Inc. (NASDAQ:SRTS) Sees Large Increase in Short Interest
marketbeat.com - March 28 at 11:58 AM
Sensus Healthcare Inc.Sensus Healthcare Inc.
wsj.com - March 23 at 2:11 AM
Sensus Healthcare to Participate in the 36th Annual Roth ConferenceSensus Healthcare to Participate in the 36th Annual Roth Conference
globenewswire.com - March 14 at 4:05 PM
Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual MeetingSensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting
globenewswire.com - March 13 at 8:00 AM
A Market With a HangoverA Market With a Hangover
realmoney.thestreet.com - March 11 at 1:19 PM
3 Stocks to Buy That Are Up 100% or More in 20243 Stocks to Buy That Are Up 100% or More in 2024
investorplace.com - February 25 at 2:02 PM
Sensus Healthcare (SRTS) Price Target Increased by 24.07% to 6.83Sensus Healthcare (SRTS) Price Target Increased by 24.07% to 6.83
msn.com - February 24 at 4:42 AM
Sensus Healthcare Stock (NASDAQ:SRTS) Earnings Dates and Earning CallsSensus Healthcare Stock (NASDAQ:SRTS) Earnings Dates and Earning Calls
benzinga.com - February 23 at 5:28 PM
My Current Game Plan Includes Adding This Small-Cap Stock to My Watch ListMy Current Game Plan Includes Adding This Small-Cap Stock to My Watch List
realmoney.thestreet.com - February 21 at 8:19 PM
Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?
finance.yahoo.com - February 12 at 12:53 PM
Sensus Healthcare, Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesSensus Healthcare, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
finance.yahoo.com - February 11 at 10:42 AM
Sensus Healthcare: Strong Q4 Performance and Promising Future Drive Buy RatingSensus Healthcare: Strong Q4 Performance and Promising Future Drive Buy Rating
markets.businessinsider.com - February 10 at 3:48 PM
Sensus Healthcare, Inc. (SRTS) Q4 2023 Earnings Call TranscriptSensus Healthcare, Inc. (SRTS) Q4 2023 Earnings Call Transcript
seekingalpha.com - February 9 at 7:12 PM
Sensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2023 Earnings Call TranscriptSensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 9 at 2:11 PM
Q4 2023 Sensus Healthcare Inc Earnings CallQ4 2023 Sensus Healthcare Inc Earnings Call
finance.yahoo.com - February 9 at 9:10 AM
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial ResultsSensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
markets.businessinsider.com - February 8 at 7:56 PM
Sensus Healthcare announces U.S. patent for SRT-100 Vision SystemSensus Healthcare announces U.S. patent for SRT-100 Vision System
msn.com - February 8 at 9:55 AM
Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) CapabilitiesSensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities
finance.yahoo.com - February 8 at 9:55 AM
Earnings Preview For Sensus HealthcareEarnings Preview For Sensus Healthcare
benzinga.com - February 7 at 3:46 PM
Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory RequirementsSensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements
finance.yahoo.com - February 6 at 1:04 PM
Sensus Healthcare Announces Director Samuel O’Rear’s RetirementSensus Healthcare Announces Director Samuel O’Rear’s Retirement
msn.com - February 3 at 9:40 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bioventus logo

Bioventus

NYSE:BVS
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
DarioHealth logo

DarioHealth

NASDAQ:DRIO
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Nyxoah logo

Nyxoah

NASDAQ:NYXH
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Sensus Healthcare logo

Sensus Healthcare

NASDAQ:SRTS
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.